CN113041246B - 一种防治脱发的姜黄素组合物 - Google Patents
一种防治脱发的姜黄素组合物 Download PDFInfo
- Publication number
- CN113041246B CN113041246B CN202110301452.3A CN202110301452A CN113041246B CN 113041246 B CN113041246 B CN 113041246B CN 202110301452 A CN202110301452 A CN 202110301452A CN 113041246 B CN113041246 B CN 113041246B
- Authority
- CN
- China
- Prior art keywords
- curcumin
- hair
- composition
- pdo
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims abstract description 109
- 239000004148 curcumin Substances 0.000 title claims abstract description 55
- 229940109262 curcumin Drugs 0.000 title claims abstract description 51
- 235000012754 curcumin Nutrition 0.000 title claims abstract description 51
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 38
- 231100000360 alopecia Toxicity 0.000 title claims abstract description 20
- SKQIRRPTHXKMFU-UHFFFAOYSA-N N1(CCCC1)C1=[N+](C(=CC(=N1)N)N)[O-] Chemical compound N1(CCCC1)C1=[N+](C(=CC(=N1)N)N)[O-] SKQIRRPTHXKMFU-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 11
- 208000024963 hair loss Diseases 0.000 claims description 8
- 230000003676 hair loss Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims 1
- 201000002996 androgenic alopecia Diseases 0.000 abstract description 10
- 206010068168 androgenetic alopecia Diseases 0.000 abstract description 8
- 210000004209 hair Anatomy 0.000 description 29
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- 230000003779 hair growth Effects 0.000 description 11
- 229960003604 testosterone Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003778 catagen phase Effects 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000234299 Zingiberaceae Species 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- VFYWLVNRQKDHHQ-UHFFFAOYSA-N 3-n-(cyclohexylideneamino)-1,2,5-oxadiazole-3,4-diamine Chemical compound NC1=NON=C1NN=C1CCCCC1 VFYWLVNRQKDHHQ-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 244000045195 Cicer arietinum Species 0.000 description 1
- 235000010523 Cicer arietinum Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000012399 oncology drug development Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及医药学领域，特别是涉及一种防治脱发的组合物及其用途，所述组合物由吡咯烷基二氨基嘧啶氧化物和姜黄素按重量比9:1～1:9制成。本发明的组合物可用于防治雄激素性脱发。
Description
技术领域
本发明属于医药领域。具体涉及一种防治脱发的药物组合物。
背景技术
脱发对个人的心理健康和生活质量产生显著影响，是许多患者自尊心低和焦虑的源头，严重者会导致抑郁症的发生。正常脱落的头发一般是处于退行期及休止期的毛发，由于进入退行期与进入生长期的毛发不断处于动态平衡，故能维持正常数量的毛发。病理性脱发是指头发异常或过度的脱落，导致病理性脱发的因素包括遗传、精神压力、自身免疫、急慢性传染病、各种皮肤病、内分泌失调、化疗毒副作用等。雄激素性脱发（androgeneticalopecia，AGA）又称脂溢性脱发，属于病理性脱发，占脱发人群的90%以上，以头皮油腻、瘙痒、头屑、脱发等为主要表现，是临床最常见的脱发类型，是由于内分泌失调造成的，不同于化疗毒副作用，多见于20-30岁的青壮年男性，以头部及顶部毛发进行性减少为特征，大多在青春期出现，随年龄症状加重。男性女性都存在雄激素性脱发，但在男性中更为常见。至今，美国FDA仅批准了两种治疗雄激素性脱发药物：适用于男女性的米诺地尔酊剂和仅适用于男性的口服非那雄胺片，二者均有显著的副作用，且停药易复发。
姜黄素是从姜科植物姜黄中提取的一种多酚类成分，也存在其它姜科植物中。现代研究发现姜黄素的主要药理作用有抗氧化、抗炎、抗凝、降脂、抗动脉粥样硬化、抗衰老消除自由基及抑制肿瘤生长等作用。吡咯烷基二氨基嘧啶氧化物（Pyrrolidinyldiaminopyrimidine oxide，PDO）是一种能促进头发生长的化合物，可促进毛乳头细胞的增值，恢复毛囊活力。
发明内容
本发明的目的旨在提供一种防治脱发的组合物。
具体地说，本发明提供了一种防治脱发的组合物，所述组合物由由吡咯烷基二氨基嘧啶氧化物和姜黄素按重量比9 : 1 ~ 1 : 9制成。
在一优选例中，所述脱发为雄激素性脱发。
在另一优选例中，所述吡咯烷基二氨基嘧啶氧化物和姜黄素的重量比为4 : 1 ~1 : 4。
在另一优选例中，所述吡咯烷基二氨基嘧啶氧化物和姜黄素的重量比为7 : 3 ~3 : 7。
在另一优选例中，所述吡咯烷基二氨基嘧啶氧化物和姜黄素的重量比为3 : 2 ~2 : 3。
在另一优选例中，所述吡咯烷基二氨基嘧啶氧化物和姜黄素的重量比为1 : 1。
本发明还提供了上述组合物在制备防治脱发的药物中的用途。
本发明各个方面的细节将在随后的章节中得以详尽描述。通过下文以及权利要求的描述，本发明的特点、目的和优势将更为明显。
具体实施方式
本发明的问世部分是基于这样一个意外发现：吡咯烷基二氨基嘧啶氧化物与姜黄素组合物外用涂剂可促进睾酮诱导的雄激素性脱发小鼠模型的毛发生长且比单用吡咯烷基二氨基嘧啶氧化物或单用姜黄素效果更好。因此，吡咯烷基二氨基嘧啶氧化物与姜黄素组合物外用涂剂可用于制备防治脱发，特别是雄激素性脱发的药物等。
本发明的吡咯烷基二氨基嘧啶氧化物可通过商业途径从 北京沃凯生物科技有限公司购买获得。本发明的姜黄素的分子式：C21H20O6，分子量：368.38，其结构式如下：
。
本发明的姜黄素可从上海源叶生物有限公司获得，其纯度均符合药用标准。
组合物中“可药用载体”不会破坏本发明的吡咯烷基二氨基嘧啶氧化物及姜黄素的药学活性，同时其有效用量，即能发挥药物载体作用时的用量对人体无毒。
所述可药用载体包括但不限于：软磷脂、硬脂酸铝、氧化铝、离子交换材料、自乳化药物传递系统、吐温或其他表面活化剂、血清蛋白、缓冲物质如磷酸盐、氨基乙酸、山梨酸、水、盐、电解质如硫酸盐精蛋白、磷酸氢二钠、磷酸氢钾、氯化钠、锌盐、硅酸镁、饱和脂肪酸部分甘油酯混合物等。
其他常用的药物辅料如粘合剂（如微晶纤维素）、填充剂（如淀粉、葡萄糖、无水乳糖和乳糖珠粒）、崩解剂（如交联PVP、交联羧甲基淀粉钠、交联羧甲基纤维素钠、低取代羟丙基纤维素）、润滑剂（如硬脂酸镁）以及吸收促进剂、吸附载体、香味剂、甜味剂、赋形剂、稀释剂、润湿剂等。
本发明的吡咯烷基二氨基嘧啶氧化物及姜黄素组合物按本领域的常规方法制成药物。
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件或按照制造厂商所建议的条件。除非另外说明，否则所有的百分数、比率、比例、或份数按重量计。
除非另行定义，文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外，任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。
本发明提到的上述特征，或实施例提到的特征可以任意组合。本专利说明书所揭示的所有特征可与任何组合物形式并用，说明书中所揭示的各个特征，可以任何可提供相同、均等或相似目的的替代性特征取代。因此除有特别说明，所揭示的特征仅为均等或相似特征的一般性例子。
实施例一
1.实验材料
1.1药材
睾酮（CAS：58-22-0，分子量288.42，HPLC纯度≥98%，由美国Sigma-Aldrich公司生产）；姜黄素（CAS号: 458-37-7，分子量368.38，HPLC纯度≥98%，上海源叶生物有限公司）；吡咯烷基二氨基嘧啶氧化物（简写PDO，CAS:55921-65-8，分子式C8H13N5O，分子量195.22，HPLC纯度≥98%， 北京沃凯生物科技有限公司）
1.2实验动物
体重20±2g的C57BL/6雄性小鼠（8周），由上海中医药大学实验动物中心提供，动物合格证号：SYXK（沪）2009-0069。置于常规饲养环境，自由进食和饮水。
2. 实验方法
2.1吡咯烷基二氨基嘧啶氧化物及姜黄素组合物的配制
（1）取3g PDO粉末加入100ml 1,2丙二醇搅拌混匀，制成3%PDO溶液；
（2）取3g姜黄素粉末加入100ml1,2丙二醇搅拌混匀，制成3%姜黄素溶液；
（3）各取3%PDO溶液和3%姜黄素溶液按照9:1，8:2，7:3，6:4，5:5，4:6，3:7，2:8，1:9的比例搅拌混匀得到不同浓度的PDO+姜黄素组合物外用涂剂（分别为2.7%PDO+0.3%姜黄素，2.4%PDO+0.6%姜黄素，2.1%PDO+0.9%姜黄素，1.8%PDO+1.2%姜黄素，1.5%PDO+1.5%姜黄素，1.2%PDO+1.8%姜黄素，0.9%PDO+2.1%姜黄素，0.6%PDO+2.4%姜黄素，0.3%PDO+2.7%姜黄素），即下面的组合物组。
2.2雄激素性脱发小鼠模型的建立及分组涂样
雄激素性脱发小鼠模型的建立参照文献（鹰嘴豆素A对病理脱发模型小鼠毛发生长影响的初步研究. 天然产物研究与开发. 2014, 26: 613~618）。选择体重均一的C57BL/6雄性小鼠（20±2g）适应饲养1周，用松香、石蜡混合加热溶化冷却后涂于小鼠背部去除毛发，诱导小鼠毛囊由静止期进入生长期，此时毛囊与自发形成的生长期毛囊在形态上无差别，皮肤呈粉红色。脱毛第二天各组小鼠背部试验区域按以下方法进行动物分组及涂样：
空白对照组：涂抹溶剂30min后，涂抹空白基质；
模型组：涂抹0.1%睾酮30min后，涂抹空白基质；
PDO组：涂抹0.1%睾酮30min后，涂抹3% PDO（制备方法见2.1）；
姜黄素组：涂抹0.1%睾酮30min后，涂抹3%姜黄素（制备方法见2.1）；
PDO+姜黄素组：涂抹0.1%睾酮30min后，涂抹组合物（制备方法见2.1）；
2.3评价指标
2.3.1毛长测量：涂药第15d，18d和21d，分别拔去脱毛区域前、中、后部各3搓毛发，测量其长度，取平均值。
2.3.2毛重测量：第21天后处死小鼠，在脱毛区域沿毛发根部剪下3*3cm面积的毛发，分析天平称重，求其平均值。
2.3.3协同分数：协同分数通过Clarke R .Issues in experimental design andendpoint analysis in the study of experimental cytotoxic agents in vivo inbreast cancerand other models[J]. Breast Cancer Research&Treatment,1997,46(2-3):255-278描述的公式计算，其全文通过引用并入本文：
协同分数＝((A/C)×(B/C))/(AB/C)；
其中A为药物PDO的毛长或毛重值；B为药物姜黄素的毛长或毛重值；C为模型组的毛长或毛重值；AB为PDO、姜黄素联合疗法的毛长或毛重值。协同分数：>1表示协同效应，＝1为叠加效应，<1为拮抗效应(参照Gould SE等，Translational value of mouse models inoncology drug development. Nature medicine. 201521,431-439)。
2.4 统计分析
所有实验数据均重复3次，结果以平均值±标准差表示，采用SPSS 16.0统计软件对实验数据采用单向方差分析（One-way ANOVA）及LSD检验，P<0.05为统计学上差异有显著性。
3. 结果
3.1 吡咯烷基二氨基嘧啶氧化物及姜黄素组合物对毛长的影响
表1体现了吡咯烷基二氨基嘧啶氧化物及姜黄素组合物对毛发长度的影响。选取造模第15、18、21天的毛发长度来分析，空白对照组毛发生长较多，和脱发模型组相比有显著差异（P＜0.001），说明睾酮可抑制毛发生长，模型建立成功； PDO组、姜黄素组和组合物组均可促进毛发生长，与脱发模型组相比有显著的差异（P＜0.05或P＜0.01或P<0.001）。其中不同比例的组合物组（PDO与姜黄素按照比例9:1，8:2，7:3，6:4，5:5，4:6，3:7，2:8，1:9）对毛发生长的促进作用最强，与单用PDO组及单用姜黄素组相比均有显著差异（第15天，组合物组
vsPDO组：P＜0.05，组合物组
vs姜黄素组：P＜0.05，协同分数均＞1；第18天，组合物组
vsPDO组：P＜0.05或P＜0.01，组合物组
vs姜黄素组：P＜0.05或P＜0.01，协同分数均＞1；第21天，组合物组
vsPDO组：P＜0.05或P＜0.01，组合物组
vs姜黄素组：P＜0.05或P＜0.01，协同分数均＞1）。表明组合物在刺激毛发生长方面显著优于单用PDO或单用姜黄素。
3.2 吡咯烷基二氨基嘧啶氧化物及姜黄素组合物对毛重的影响
表2体现了吡咯烷基二氨基嘧啶氧化物及姜黄素组合物对小鼠毛重的影响。在第21天处死小鼠，选取脱毛区域，剪下2*2cm面积的毛发，分析天平称重发现空白对照组毛重是82.07±15.74mg，脱发模型组毛重是11.52±3.31mg，PDO组毛重是33.54±6.48mg，姜黄素组毛重是27.82±3.16mg，组合物组毛重是55.84±6.37mg，说明PDO组、姜黄素组和组合物组均可促进毛发生长，且与脱发模型组相比均有显著性差异（P＜0.05或P＜0.01或P<0.001）。其中不同比例的组合物组（PDO与姜黄素按照比例9:1，8:2，7:3，6:4，5:5，4:6，3:7，2:8，1:9）对毛发生长的促进作用最强，与单用PDO组及单用姜黄素组相比均有显著差异（组合物组
vsPDO组：P＜0.05或P＜0.01，组合物组
vs姜黄素组：P＜0.01或P＜0.001，协同分数均＞1）。表明组合物在刺激毛发生长方面显著优于单用PDO或单用姜黄素。
表1
表2
综上研究结果表明，吡咯烷基二氨基嘧啶氧化物与姜黄素组合物外用涂剂可刺激毛发的生长，治疗雄激素性脱发，作用效果优于单用吡咯烷基二氨基嘧啶氧化物或单用姜黄素。
本发明所涉及的多个方面已做如上阐述。然而，应理解的是，在不偏离本发明精神之前提下，本领域专业人员可对其进行等同改变和修饰，所述改变和修饰同样落入本申请所附权利要求的覆盖范围。
Claims (7)
1.一种防治脱发的组合物，其特征在于，所述组合物由吡咯烷基二氨基嘧啶氧化物和姜黄素按重量比9 : 1 ~ 1 : 9制成。
2.如权利要求1所述的组合物，其特征在于，所述脱发为雄激素性脱发。
3.如权利要求1或2所述的组合物，其特征在于，所述吡咯烷基二氨基嘧啶氧化物和姜黄素的重量比为4 : 1 ~ 1 : 4。
4.如权利要求1或2所述的组合物，其特征在于，所述吡咯烷基二氨基嘧啶氧化物和姜黄素的重量比为7 : 3 ~ 3 : 7。
5.如权利要求1或2所述的组合物，其特征在于，所述吡咯烷基二氨基嘧啶氧化物和姜黄素的重量比为3 : 2 ~ 2 : 3。
6.如权利要求1或2所述的组合物，其特征在于，所述吡咯烷基二氨基嘧啶氧化物和姜黄素的重量比为1 : 1。
7.如权利要求1或2所述的组合物在制备防治脱发的药物中的用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110301452.3A CN113041246B (zh) | 2021-03-22 | 2021-03-22 | 一种防治脱发的姜黄素组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110301452.3A CN113041246B (zh) | 2021-03-22 | 2021-03-22 | 一种防治脱发的姜黄素组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113041246A CN113041246A (zh) | 2021-06-29 |
| CN113041246B true CN113041246B (zh) | 2023-04-28 |
Family
ID=76514229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110301452.3A Active CN113041246B (zh) | 2021-03-22 | 2021-03-22 | 一种防治脱发的姜黄素组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113041246B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101193952B1 (ko) * | 2012-02-09 | 2012-10-24 | 주식회사 태후코스메틱 | 두피 탈모 방지 및 발모를 촉진하는 화장료 조성물 |
| CN109528725A (zh) * | 2019-01-15 | 2019-03-29 | 华中科技大学 | 一种含二氨基嘧啶氧化物和吡咯烷基二氨基嘧啶氧化物的纳米组合物及其制备方法与应用 |
| CN110917062A (zh) * | 2019-12-18 | 2020-03-27 | 广州韩金靓化妆品有限公司 | 一种促进毛发生长的纳米乳液及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190110969A1 (en) * | 2017-10-17 | 2019-04-18 | North Star Scientific, Inc. | Hair growth compositions and methods of use |
-
2021
- 2021-03-22 CN CN202110301452.3A patent/CN113041246B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101193952B1 (ko) * | 2012-02-09 | 2012-10-24 | 주식회사 태후코스메틱 | 두피 탈모 방지 및 발모를 촉진하는 화장료 조성물 |
| CN109528725A (zh) * | 2019-01-15 | 2019-03-29 | 华中科技大学 | 一种含二氨基嘧啶氧化物和吡咯烷基二氨基嘧啶氧化物的纳米组合物及其制备方法与应用 |
| CN110917062A (zh) * | 2019-12-18 | 2020-03-27 | 广州韩金靓化妆品有限公司 | 一种促进毛发生长的纳米乳液及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| Harisha.s, etal.CLINICAL TRIALS OF WATER BASED COMPOSITIONS OF ACTIVE HAIR GROWTH STIMULANTS IN THE TREATMENT OF ALOPECIA.《EUROPEAN JOURNAL OF BIOMEDICAL PHARMACEUTICAL SCIENCES》.2014,第1卷(第3期),284-305. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113041246A (zh) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6447762B1 (en) | Hair lotion useful for treatment of hair loss and stimulating hair growth | |
| CA2519980A1 (en) | Prevention and treatment of breast cancer with 4-hydroxy tamoxifen | |
| CN110917062A (zh) | 一种促进毛发生长的纳米乳液及其制备方法 | |
| EP0123528B1 (en) | Pharmaceutical composition for the treatment of hair loss | |
| CN113041246B (zh) | 一种防治脱发的姜黄素组合物 | |
| JPH06128125A (ja) | 養毛料 | |
| CN112915176B (zh) | 一种防治脱发的草豆蔻组合物 | |
| TWI758437B (zh) | 水田芥水性萃取物與金蓮花水性萃取物及三磷酸腺苷（ａｔｐ）之組合於治療禿髮之技術 | |
| EP1317239B1 (fr) | Associations synergiques a base de plantes pour traiter la chute des cheveux | |
| KR102530037B1 (ko) | 타베르소닌을 포함하는 탈모방지 및 발모 촉진용 조성물 | |
| CN109044996B (zh) | 五味子醇甲的医药用途 | |
| JP2021532150A (ja) | ヘアケアの分野において使用するためのレスペデザ・カピタータ抽出物 | |
| KR102386651B1 (ko) | 티플락스티닌을 유효성분으로 함유하는 탈모 예방 또는 치료용 조성물 | |
| RU2799324C2 (ru) | Экстракт леспедецы головчатой для применения в области ухода за волосами | |
| CN113546129A (zh) | 薤白提取物的新用途 | |
| KR20090059230A (ko) | 탈모예방, 항염작용, 모근세포 활성화 및 모발생장을촉진하는 화장료 조성물 | |
| AU2022258658A1 (en) | Hair serum and supplement | |
| KR102611504B1 (ko) | 키레놀을 포함하는 탈모방지 및 발모촉진용 조성물 | |
| CN117731672A (zh) | 一种促毛发生长的制剂及其制备方法和应用 | |
| RU2116790C1 (ru) | Наружное противоинфекционное средство "рефарм" | |
| JP3337845B2 (ja) | 養毛料組成物 | |
| US20080206354A1 (en) | Composition for Improving Hair Growth Comprising an Non-Polar Solvent-Soluble Extract of Cantharis as an Active Ingredient | |
| KR20150085671A (ko) | 진세노사이드 C-Mx1을 포함하는 두피 및 모근 강화를 통한 모발 성장 촉진용 샴푸 및 컨디셔너 조성물 | |
| JPH03167111A (ja) | 養毛剤 | |
| KR20150085964A (ko) | 워고닌을 포함하는 모발 성장 촉진용 화장료 또는 약학 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |